Dexcom has unveiled an exciting new addition to its continuous glucose monitors (CGMs) lineup with the launch of Stelo, an over-the-counter (OTC) CGM biosensor.
Dexcom has specifically designed Stelo for individuals with type 2 diabetes who do not require insulin therapy. The device is a compact, wearable sensor built on the advanced G7 platform, offering a 15-day usage period. Stelo is equipped with a software interface tailored to meet the needs of non-insulin users, making it a highly specialized tool for managing glucose levels.
The introduction of Stelo aims to simplify access to continuous glucose monitoring for those who might otherwise face barriers due to lack of insurance coverage or other challenges. The system will be sold at pharmacies across the U.S.
Image Credit: Dexcom
What's Driving This Trend
- Wearable Glucose Monitors
- Wearable glucose monitors like Dexcom Stelo are revolutionizing diabetes management by providing real-time glucose tracking without the need for invasive procedures.
- Over-the-counter Medical Devices
- The market for over-the-counter medical devices is expanding, as seen with Stelo, offering easier access to advanced healthcare solutions without requiring a prescription.
- Non-insulin Diabetes Management
- Tailored solutions for non-insulin diabetes management are becoming more prevalent, providing specialized tools like Stelo to cater to the unique needs of type 2 diabetes patients.
Who This Affects Most
- Healthcare Technology
- Healthcare technology companies are advancing the field with innovative devices like Stelo, which integrate cutting-edge biosensor technology with user-friendly software.
- Pharmaceutical Retail
- Pharmaceutical retail is witnessing a shift towards stocking advanced over-the-counter medical devices such as the Dexcom Stelo, enhancing accessibility for patients.
- Diabetes Care
- The diabetes care industry is evolving rapidly with new solutions like Stelo, which focus on non-insulin interventions and cater to broader patient demographics.
